Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Migraine

Migraine

Subtypes of Migraine

Episodic Migraine 3 Vestibular migraine 2 Abdominal migraine 1 Migraine with or without aura 0

17 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Migraine

220 trials tracked for Migraine: 118 in phase 3 or 4 and 55 with published results. The most-cited published study has 350 citations.

220Trials tracked
118Phase 3 & 4
0Recruiting
55With published results
Phase distribution
Phase 4 50 Phase 3 68 Phase 2 32 Phase 1 16 Other / NA 54
  1. Phase 3 Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults Completed · 350 cited
  2. Phase 4 Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine Completed · 177 cited
  3. Phase 3 Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine Completed · 176 cited
  4. Phase 3 Randomized Trial in Adult Participants With Acute Migraines Completed · 144 cited
  5. Phase 3 A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura Completed · 141 cited
  6. Phase 3 Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine Completed · 129 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine Completed · 103 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention Completed · 96 cited
  3. Phase 3 Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants Completed · 83 cited
  4. Phase 4 Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine Completed · 79 cited
  5. Phase 3 Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine Completed · 70 cited
  6. Phase 3 Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine Completed · 67 cited
  7. Phase 3 Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura Completed · 54 cited
  8. Phase 4 Diphenhydramine for Acute Migraine Completed · 47 cited
  9. Phase 3 Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study Completed · 43 cited
  10. Phase 3 Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study Completed · 43 cited
  11. Phase 4 A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Completed · 41 cited
  12. Phase 3 Evaluation of Galcanezumab in the Prevention of Chronic Migraine Completed · 41 cited
  13. Phase 3 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention Completed · 41 cited
  14. Phase 4 Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action Completed · 37 cited
  15. Phase 3 A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine Completed · 32 cited
  16. Phase 4 Imaging the Migraine Brain Pre- and Post-Erenumab Completed · 31 cited
  17. Phase 4 Ticagrelor Therapy for RefrACTORy Migraine Study Completed · 30 cited
  18. Phase 3 Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients Completed · 30 cited
  19. Phase 3 Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine Completed · 29 cited
  20. Phase 3 A Study of Lasmiditan (LY573144) Over Four Migraine Attacks Completed · 26 cited
  21. Phase 3 DFN-02 Open Label Safety Study in Patients With Acute Migraine Completed · 24 cited
  22. Phase 4 Effect of Acetyl-L-carnitine in Migraine Completed · 23 cited
  23. Phase 3 A Controlled Trial of Erenumab in Migraine Prevention Completed · 22 cited
  24. Phase 3 Lasmiditan Compared to Placebo in the Acute Treatment of Migraine: Completed · 21 cited
  25. Phase 4 Corticosteroids for Acute Migraine in the Emergency Department Completed · 20 cited
  26. Phase 4 A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder Completed · 18 cited
  27. Phase 3 Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine Completed · 17 cited
  28. Phase 4 Biomarker and Genetic Predictors of Erenumab Treatment Response Completed · 15 cited
  29. Phase 3 A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine Completed · 15 cited
  30. Phase 3 A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine Completed · 14 cited
  31. Phase 3 Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine Completed · 14 cited
  32. Phase 3 Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine Completed · 14 cited
  33. Phase 4 Treatment of Insomnia in Migraineurs Completed · 13 cited
  34. Phase 3 Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only) Completed · 12 cited
  35. Phase 3 Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine Completed · 10 cited
  36. Phase 3 Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine Completed · 10 cited
  37. Phase 4 Dexamethasone for Migraine - Dose Comparison Completed · 9 cited
  38. Phase 3 Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only) Completed · 7 cited
  39. Phase 3 A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age Completed · 7 cited
  40. Phase 3 A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Completed · 5 cited
  41. Phase 4 Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Completed · 4 cited
  42. Phase 4 Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications Completed · 4 cited
  43. Phase 3 A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments Completed · 4 cited
  44. Phase 4 Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use Completed · 3 cited

Showing the 50 most-cited and recently-updated of 220 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Neurotological evaluation distinguishes vestibular migraine from viral neuritis in acute unilateral vestibulopathy
ENT (Otolaryngology) Sys. Review
Neurotological evaluation distinguishes vestibular migraine from viral neuritis in acute unilateral vestibulopathy A single case report shows rapid recovery in vestibular migraine
This case report describes a 40-year-old woman with a history of migraine with aura presenting to the emergency department with vestibular m…
A 40-year-old woman with vestibular migraine recovered her balance quickly. This case suggests that specific reflex patterns help doctors te…
Frontiers Jun 4, 2026
Post-marketing data on CGRP inhibitors show paucity of data and additional risks from chronic biologic use
Drug Pipeline Sys. Review
Post-marketing data on CGRP inhibitors show paucity of data and additional risks from chronic biologic use Post-marketing review highlights safety gaps for migraine CGRP drugs
This narrative review examines monoclonal antibodies and Calcitonin Gene-Related Peptide (CGRP) inhibitors for migraine in the post-marketin…
A review of migraine treatments notes limited data on long-term risks for CGRP inhibitors, urging caution during active monitoring.
Frontiers May 29, 2026
Asia-Pacific experts reach consensus on migraine management and anti-CGRP mAb use in adolescents
Neurology Guideline
Asia-Pacific experts reach consensus on migraine management and anti-CGRP mAb use in adolescents Asia-Pacific experts find consensus on migraine diagnosis and treatment
This guideline presents a Delphi consensus involving 14 headache specialists from seven Asia-Pacific countries. The group evaluated statemen…
Headache specialists across Asia-Pacific agree on key migraine diagnosis and treatment steps, favoring anti-CGRP drugs for most patients but…
Frontiers May 28, 2026
Bayesian network meta-analysis compares CGRP therapies for episodic migraine
Neurology Meta-analysis
Bayesian network meta-analysis compares CGRP therapies for episodic migraine New migraine drugs show big benefits over placebo for monthly attack counts
This Bayesian network meta-analysis synthesized evidence on six CGRP-targeted therapies for episodic migraine. It found that monoclonal anti…
New migraine drugs cut monthly attacks more than placebo, with injectables slightly better than pills for some people.
medRxiv May 25, 2026
Narrative review refutes causal link between endometriosis and migraine
Neurology Sys. Review
Narrative review refutes causal link between endometriosis and migraine Endometriosis and Migraine Share Hidden Genetic Roots
This narrative review examines the association between endometriosis and migraine. The authors refute a causal relationship and discuss shar…
New genetic research suggests endometriosis and migraine are parallel conditions driven by shared inflammatory pathways, not just hormones.
Frontiers May 15, 2026
Systematic review and meta-analysis compares Rome III and Rome IV criteria for functional abdominal pain disorder prevalence
Pediatrics Meta-analysis
Systematic review and meta-analysis compares Rome III and Rome IV criteria for functional abdominal pain disorder prevalence New Rome IV rules show fewer people have functional abdominal pain compared to older guidelines
This systematic review and meta-analysis evaluates the prevalence of functional abdominal pain disorder (FAPD) and its subtypes using Rome I…
A big review found that using newer rules makes it look like fewer people have stomach pain problems. This change happens because the new ch…
May 15, 2026
Meta-analysis of Chinese decoctions for migraine shows varied efficacy rankings across three botanical interventions.
Drug Pipeline Meta-analysis
Meta-analysis of Chinese decoctions for migraine shows varied efficacy rankings across three botanical interventions. New analysis ranks best herbal treatments for migraine pain
This Bayesian network meta-analysis synthesizes data from 57 randomized controlled trials involving 6,005 patients with migraine.
A new analysis of dozens of Chinese herbal formulas reveals which ones may ease migraine pain, frequency, and duration better than others, o…
Frontiers May 1, 2026
Individualized probabilistic migraine forecasts delivered via electronic diaries in adults with recurrent headaches
Neurology Cohort
Individualized probabilistic migraine forecasts delivered via electronic diaries in adults with recurrent headaches Migraine Forecasting Just Got Smarter
This prospective cohort study of 230 adults with recurrent migraine or tension-type headache evaluated individualized probabilistic forecast…
This tool could help you prepare for migraines before they strike.
medRxiv Apr 23, 2026
Observational cohort study on smartphone-based cognitive assessment during migraine attacks
Neurology
Observational cohort study on smartphone-based cognitive assessment during migraine attacks At-a-Glance
This primary research article is an observational cohort study of 139 adults with migraine using smartphone-based cognitive tasks.
This study proves that your brain's processing speed and memory can dip during a migraine attack, and a simple smartphone app can now track …
medRxiv Apr 23, 2026
Feasibility of 30-day smartphone assessment in 177 adults with migraine
Neurology Cohort
Feasibility of 30-day smartphone assessment in 177 adults with migraine Smartphones Track Migraine Brain Fog Better Than Doctor Visits
This cohort study assessed the feasibility of a 30-day smartphone-based assessment involving once-daily ecological momentary assessments and…
Imagine trying to remember your keys during a severe migraine.
medRxiv Apr 21, 2026
Add-on atogepant 60 mg daily reduced monthly migraine days in chronic migraine patients on stable onabotulinumtoxinA
Drug Pipeline Phase III
Add-on atogepant 60 mg daily reduced monthly migraine days in chronic migraine patients on stable onabotulinumtoxinA Adding atogepant to botulinum toxin reduced migraine days in a small study
This Phase 3, multicenter, 24-week, open-label, single arm study evaluated add-on atogepant 60 mg once daily in 75 participants with chronic…
Adding atogepant to botulinum toxin cut migraine days by over 50% for 62% of patients in a study, with most finding it safe and well-tolerat…
Apr 18, 2026
Narrative review explores fMRI utility in otolaryngology disorders including tinnitus and vestibular migraine
Neurology Sys. Review
Narrative review explores fMRI utility in otolaryngology disorders including tinnitus and vestibular migraine The Brain Scan Changing How Doctors See Hearing and Balance Problems
This narrative review examines the application of functional magnetic resonance imaging (fMRI) in patients with otolaryngology–head and neck…
A new brain scan shows that tinnitus and hearing loss aren't just ear problems, but actually change how the brain works.
Frontiers Apr 18, 2026

Questions about Migraine

What are the real-world results of using eptinezumab for ongoing episodic or chronic migraine attacks?

Real-world data from the BE-FREE study shows that eptinezumab reduces pain intensity and associated symptoms like light sensitivity within 10 to 20 minutes of infusion for patients with ongoing migraine attacks.

Full answer →
Does eptinezumab plus education reduce migraine days in chronic migraine patients who overuse medication?

Yes, a 12-week trial found that eptinezumab combined with a brief educational intervention reduced monthly migraine days in adults with chronic migraine and medication overuse.

Full answer →
How does resting-state fMRI show brain entropy differences in chronic migraine compared to healthy controls?

Resting-state fMRI shows that people with chronic migraine have lower brain entropy in key brain networks compared to healthy people, and this difference is even greater in chronic migraine than in episodic migraine.

Full answer →
Does intravenous eptinezumab help reduce pain and symptoms during an ongoing chronic migraine attack?

Yes, intravenous eptinezumab can reduce pain and symptoms during an ongoing chronic migraine attack, with effects seen within 10-30 minutes of infusion.

Full answer →
Does resting-state fMRI show different brain activity in people with chronic migraine?

Yes, resting-state fMRI shows reduced brain entropy and altered low-frequency brain activity in people with chronic migraine compared to healthy controls.

Full answer →
Can a smartphone app accurately predict when my migraine attacks will happen?

Smartphone apps can provide short-term predictions for migraine attacks, but current models only predict about a 59% chance of an attack occurring within 24 hours, which is only slightly better than random guessing.

Full answer →
See all 6 questions about Migraine →

All Migraine Articles